CirrhoCare®评估:一种用于肝硬化患者居家管理的数字健康解决方案
本研究评估CirrhoCare®远程管理急性失代偿期肝硬化出院患者的可行性与潜在临床获益,采用20例CirrhoCare®管理患者与20例同期匹配对照比较。结果显示患者参与度良好,CirrhoCare®组再入院次数更少、住院更短,非计划性腹腔穿刺更少,但研究为试点非随机设计,结局需在更大规模随机对照试验中进一步验证。
要点
- CirrhoCare®通过智能手机应用连接商用监测设备,每日记录心率、血压、体重、体水百分比、认知功能及自报健康状况,并支持医患双向沟通。
- 20例CirrhoCare®管理患者中15例参与度良好(每周≥4次读数),可用性问卷所有问题中位评分≥9。
- CirrhoCare®组5例患者共8次再入院,中位住院5天(IQR 3.5-11),无超过14天的住院;对照组8例患者共13次再入院,中位住院7天(IQR 3-15),其中4次住院超过14天。
核心结论
- 本研究证明CirrhoCare®用于失代偿期肝硬化患者社区管理是可行的,患者参与度良好,能对新的失代偿事件发出具有临床相关性的警报。
- CirrhoCare®管理患者的再入院次数更少、住院时间更短,支持开展更大规模的对照临床试验。
- 鉴于本研究为试点非随机性质,结局需在更大规模随机对照试验中进一步验证临床有效性和成本效益。
研究设计与样本
- 本研究为可行性研究,将急性失代偿期肝硬化患者接受CirrhoCare®远程管理与同期匹配对照(接受标准随访)进行比较。
- 共纳入20例CirrhoCare®管理患者(平均年龄59±10岁,14例男性,酒精相关肝硬化80%,平均MELD-Na评分16.1±4.2),与20例同期对照在统计学上无差异。
- 随访时间10.1±2.4周。
- 由独立外部裁定者评估基于CirrhoCare®的决策适当性。
主要发现
- 20例CirrhoCare®管理患者中,15例参与度良好(每周≥4次读数),2例中等(每周2-3次),3例差(每周<2次)。
- 可用性问卷中所有问题中位评分≥9。
- CirrhoCare®组5例患者共8次再入院,中位住院5天(IQR 3.5-11),无超过14天的住院;对照组8例患者共13次再入院,中位住院7天(IQR 3-15),其中4次住院超过14天。
- CirrhoCare®组非计划性腹腔穿刺1次,对照组6次。
- 另有16次其他CirrhoCare®引导的患者接触,导致临床干预并防止了进一步进展,裁定者确认其适当性。
临床怎么用
- CirrhoCare®通过商用监测设备与智能手机应用连接,每日记录心率、血压、体重、体水百分比、认知功能(CyberLiver动物识别测试[CL-ART]应用)、自报健康状况及食物、液体和酒精摄入,并支持医患双向沟通。
- 研究显示CirrhoCare®用于失代偿期肝硬化患者社区管理可行,患者参与度良好,能对新的失代偿事件发出临床相关警报,并可能减少再入院和腹腔穿刺需求。
- 鉴于本研究为试点非随机设计,结局需在更大规模随机对照试验中进一步验证临床有效性和成本效益。
局限性
- 本研究为试点和非随机性质,结局需在更大规模随机对照试验中进一步验证,以评估临床有效性和成本效益。
- 生成的数据将促进数据建模和进一步研究,以完善CirrhoCare®算法,提高其检测敏感性和实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Individuals with cirrhosis discharged from hospital following acute decompensation are at high risk of new complications. This study aimed to assess the feasibility and potential clinical benefits of remote management of individuals with acutely decompensated cirrhosis using CirrhoCare®. METHODS: Individuals with cirrhosis with acute decompensation were followed up with CirrhoCare® and compared with contemporaneous matched controls, managed with standard follow-up. Commercially available monitoring devices were linked to the smartphone CirrhoCare® app, for daily recording of heart rate, blood pressure, weight, % body water, cognitive function (CyberLiver Animal Recognition Test [CL-ART] app), self-reported well-being, and intake of food, fluid, and alcohol. The app had 2-way patient-physician communication. Independent external adjudicators assessed the appropriateness of CirrhoCare®-based decisions. RESULTS: Twenty individuals with cirrhosis were recruited to CirrhoCare® (mean age 59 ± 10 years, 14 male, alcohol-related cirrhosis [80%], mean model for end-stage liver disease-sodium [MELD-Na] score 16.1 ± 4.2) and were not statistically different to 20 contemporaneous controls. Follow-up was 10.1 ± 2.4 weeks. Fifteen individuals showed good engagement (≥4 readings/week), 2 moderate (2-3/week), and 3 poor (<2/week). In a usability questionnaire, the median score was ≥9 for all questions. Five CirrhoCare®-managed individuals had 8 readmissions over a median of 5 (IQR 3.5-11) days, and none required hospitalisation for >14 days. Sixteen other CirrhoCare®-guided patient contacts were made, leading to clinical interventions that prevented further progression. Appropriateness was confirmed by adjudicators. Controls had 13 readmissions in 8 individuals, lasting a median of 7 (IQR 3-15) days with 4 admissions of >14 days. They had 6 unplanned paracenteses compared with 1 in the CirrhoCare® group. CONCLUSIONS: This study demonstrates that CirrhoCare® is feasible for community management of individuals with decompensated cirrhosis with good engagement and clinically relevant alerts to new decompensating events. CirrhoCare®-managed individuals have fewer and shorter readmissions justifying larger controlled clinical trials. IMPACT AND IMPLICATIONS: As the burden of cirrhosis grows worldwide, increasing demands are being placed on limited healthcare resources, necessitating the adoption of more sustainable care models that allow for at-home patient management. The CirrhoCare® management system was developed to fill this care gap, deploying a novel combination of hardware, apps, and algorithms, to monitor and intervene in individuals at risk of new decompensation. This study highlights the possibility of reducing hospital readmissions for cirrhosis by optimising specialist community care, reducing the need for interventions such as paracentesis, while providing a more sustainable care pathway that is acceptable to patients. However, given the pilot and non-randomised nature of this study, the outcomes require further validation in a larger randomised controlled trial, to assess both clinical effectiveness and cost-effectiveness. Moreover, the data generated will also facilitate data modelling and further research to refine the CirrhoCare® algorithms to increase their detection sensitivity and utility.
引用
- Kazankov K, Novelli S, Chatterjee DA, et al. Evaluation of CirrhoCare® - a digital health solution for home management of individuals with cirrhosis. J Hepatol. 2022. PMID: 36087864. doi:10.1016/j.jhep.2022.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。